

# **Kentucky Opioid Abatement Advisory Commission**

### Meeting Agenda - Amended

October 17, 2023, 1:00 p.m. ET

Capital Complex East, 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601

View the meeting: https://youtube.com/live/r3jqxDqbJfs?feature=share.

## I. CALL TO ORDER

#### II. BUSINESS MEETING SCHEDULE

- 1. November 14, 2023, 1:00 p.m.
  - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601
- 2. December 12, 2023, 1:00 p.m.
  - 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601

#### III. MINUTES

- 1. September 12, 2023, Business Meeting
- 2. September 15, 2023, Public Hearing
- 3. September 22, 2023, Special Meeting

# IV. EXECUTIVE DIRECTOR'S UPDATE

1. Kentucky Opioid Symposium

## V. SUBCOMMITTEE BREAK OUTS

- 1. Treatment and Recovery
- 2. Prevention, Reform, and Compliance

## VI. NEW BUSINESS

- 1. Approval to Cancel Remaining Treatment and Recovery Application Review Meetings
- 2. Approval to Cancel Remaining Prevention Application Review Meetings
- 3. Approval of Calendar Year 2024 KYOAAC Business Meeting Schedule
  - a. January 9, 2024, 1:00 p.m.
  - b. February 13, 2024, 1:00 p.m.
  - c. March 12, 2024, 1:00 p.m.
  - d. April 9, 2024, 1:00 p.m.
  - e. May 14, 2024, 1:00 p.m.
  - f. June 11, 2024, 1:00 p.m.

<sup>\*</sup>All business meetings will take place at 1024 Capital Center Drive, Suite 200, Frankfort, KY 40601



## VII. EXPERT TESTIMONIES

\*\* Due to time availability and limited scheduling, the order of the following experts may change.

- 1. Mark C. Haigney, MD, FAHA, FACC Professor of Medicine and Pharmacology, Director of Cardiology, Director, Military Cardiovascular Outcomes Research (MiCOR)
- 2. Rick Doblin, Ph.D. Executive Director at Multidisciplinary Association for Psychedelic Studies (MAPS)
- 3. Robert Walsh Chief of Regulatory Affairs Branch (Retired), Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse
- 4. Walter Dunn, M.D., Ph.D. Health Sciences Assistant Clinical Professor, UCLA Department of Psychiatry, Staff Psychiatrist at Greater Los Angeles Veterans Affairs, Food and Drug Administration Advisory Committee Member, Psychopharmacologic Drugs Advisory Committee
- 5. Javier Muniz, M.D. Supervisory General Health Scientist for the Controlled Substances Initiative, Federal Drug Administration
- 6. Sidney Pykar, M.D., FACC Clinical Cardiac Electrophysiologist, Cardiac Arrhythmia Institute Medical Director
- 7. Matthew Zorn, J.D. Partner at YetterColeman LLP
- 8. Benjamin Lightburn Co-Founder and CEO, Filament Health

### VIII. PUBLIC COMMENTS AND REMARKS

- IX. UPDATES AND ANNOUNCEMENTS
- X. ADJOURNMENT